JP2021522248A5 - - Google Patents
Info
- Publication number
- JP2021522248A5 JP2021522248A5 JP2020559465A JP2020559465A JP2021522248A5 JP 2021522248 A5 JP2021522248 A5 JP 2021522248A5 JP 2020559465 A JP2020559465 A JP 2020559465A JP 2020559465 A JP2020559465 A JP 2020559465A JP 2021522248 A5 JP2021522248 A5 JP 2021522248A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cationic
- nucleic acid
- additive
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18169325 | 2018-04-25 | ||
| EP18169325.0 | 2018-04-25 | ||
| EP18189010.4 | 2018-08-14 | ||
| EP18189010 | 2018-08-14 | ||
| PCT/EP2019/060646 WO2019207061A1 (en) | 2018-04-25 | 2019-04-25 | Cryoprotective agents for particulate formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522248A JP2021522248A (ja) | 2021-08-30 |
| JP2021522248A5 true JP2021522248A5 (cg-RX-API-DMAC7.html) | 2022-04-28 |
| JP7256824B2 JP7256824B2 (ja) | 2023-04-12 |
Family
ID=66240151
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559465A Active JP7256824B2 (ja) | 2018-04-25 | 2019-04-25 | 粒子状製剤用の凍結保護剤 |
| JP2020558887A Pending JP2021522228A (ja) | 2018-04-25 | 2019-04-25 | Rnaの送達用の脂質に基づく製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558887A Pending JP2021522228A (ja) | 2018-04-25 | 2019-04-25 | Rnaの送達用の脂質に基づく製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210137840A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP4311541A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7256824B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20210021943A (cg-RX-API-DMAC7.html) |
| CN (2) | CN112153985B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019258678B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112020021037A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3098259C (cg-RX-API-DMAC7.html) |
| ES (2) | ES2960939T3 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2020011167A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3784285T3 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2019207060A1 (cg-RX-API-DMAC7.html) |
| ZA (2) | ZA202006025B (cg-RX-API-DMAC7.html) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4074693A1 (en) | 2011-06-08 | 2022-10-19 | Translate Bio, Inc. | Cleavable lipids |
| KR20220025112A (ko) | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| BR112014024131A2 (pt) | 2012-03-29 | 2017-07-25 | Shire Human Genetic Therapies | lipídios catiônicos ionizáveis |
| EA201492055A1 (ru) | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
| EA201591283A1 (ru) | 2013-03-14 | 2016-02-29 | Шир Хьюман Дженетик Терапис, Инк. | Количественная оценка эффективности кэп матричной рнк |
| KR102311614B1 (ko) | 2013-03-14 | 2021-10-08 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| US10266559B2 (en) | 2013-03-14 | 2019-04-23 | Translate Bio, Inc. | Ribonucleic acids with 4′-thio-modified nucleotides and related methods |
| MX2015011945A (es) | 2013-03-14 | 2015-12-01 | Shire Human Genetic Therapies | Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero. |
| ES2967701T3 (es) | 2013-03-15 | 2024-05-03 | Translate Bio Inc | Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas |
| ES2707966T3 (es) | 2013-10-22 | 2019-04-08 | Translate Bio Inc | Terapia de ARNm para la deficiencia en síntesis de argininosuccinato |
| ES3032935T3 (en) | 2013-10-22 | 2025-07-29 | Translate Bio Inc | Lipid formulations for delivery of messenger rna |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| AU2014340149B2 (en) | 2013-10-22 | 2020-12-24 | Shire Human Genetic Therapies, Inc. | CNS delivery of mRNA and uses thereof |
| WO2015184256A2 (en) | 2014-05-30 | 2015-12-03 | Shire Human Genetic Therapies, Inc. | Biodegradable lipids for delivery of nucleic acids |
| AU2015357562B2 (en) | 2014-12-05 | 2021-10-21 | Translate Bio, Inc. | Messenger RNA therapy for treatment of articular disease |
| AU2017283479B2 (en) | 2016-06-13 | 2023-08-17 | Translate Bio, Inc. | Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency |
| CN116549671A (zh) | 2016-11-10 | 2023-08-08 | 川斯勒佰尔公司 | 用于递送mrna的改进的基于ice的脂质纳米颗粒制剂 |
| ES2899323T3 (es) | 2017-02-27 | 2022-03-10 | Translate Bio Inc | Métodos de purificación de ARN mensajero |
| IL270631B2 (en) | 2017-05-16 | 2024-03-01 | Translate Bio Inc | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| US11530298B2 (en) | 2017-06-12 | 2022-12-20 | Translate Bio, Inc. | Poly(phosphoesters) for delivery of nucleic acids |
| US10780183B2 (en) | 2017-06-19 | 2020-09-22 | Translate Bio, Inc. | Messenger RNA therapy for the treatment of Friedreich's ataxia |
| MA51306A (fr) | 2017-12-20 | 2020-10-28 | Translate Bio Inc | Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase |
| JP7256824B2 (ja) | 2018-04-25 | 2023-04-12 | エスリス ゲーエムベーハー | 粒子状製剤用の凍結保護剤 |
| AU2019271215B2 (en) | 2018-05-16 | 2024-09-12 | Translate Bio, Inc. | Ribose cationic lipids |
| US12076439B2 (en) | 2018-05-24 | 2024-09-03 | Translate Bio, Inc. | Thioester cationic lipids |
| EP3802507A1 (en) | 2018-05-30 | 2021-04-14 | Translate Bio, Inc. | Vitamin cationic lipids |
| CN118436618A (zh) | 2018-05-30 | 2024-08-06 | 川斯勒佰尔公司 | 信使rna疫苗及其用途 |
| MA52762A (fr) | 2018-05-30 | 2021-04-14 | Translate Bio Inc | Lipides cationiques comprenant une fraction stéroïdienne |
| WO2020023533A1 (en) | 2018-07-23 | 2020-01-30 | Translate Bio, Inc. | Dry power formulations for messenger rna |
| CA3109548A1 (en) * | 2018-08-14 | 2020-02-20 | Ethris Gmbh | Lipid-based formulations containing salts for the delivery of rna |
| US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| EP3849617A1 (en) | 2018-09-14 | 2021-07-21 | Translate Bio, Inc. | Composition and methods for treatment of methylmalonic acidemia |
| CA3115119A1 (en) | 2018-11-08 | 2020-05-14 | Translate Bio, Inc. | Methods and compositions for messenger rna purification |
| AU2019384557B2 (en) | 2018-11-21 | 2025-07-17 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR |
| US12257305B2 (en) | 2018-11-21 | 2025-03-25 | Translate Bio, Inc. | Cationic lipid compounds |
| WO2020146344A1 (en) | 2019-01-07 | 2020-07-16 | Translate Bio, Inc. | Composition and methods for treatment of primary ciliary dyskinesia |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| WO2020214946A1 (en) | 2019-04-18 | 2020-10-22 | Translate Bio, Inc. | Cystine cationic lipids |
| US11453877B2 (en) | 2019-05-15 | 2022-09-27 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| EP3986858A1 (en) | 2019-06-21 | 2022-04-27 | Translate Bio, Inc. | Tricine and citric acid lipids |
| AU2020315962B2 (en) | 2019-07-23 | 2026-02-12 | Translate Bio, Inc. | Stable compositions of mRNA-loaded lipid nanoparticles and processes of making |
| CA3155003A1 (en) | 2019-09-20 | 2021-03-25 | Translate Bio, Inc. | Mrna encoding engineered cftr |
| EP4529928A3 (en) | 2019-10-09 | 2025-05-28 | Translate Bio, Inc. | Compositions, methods and uses of messenger rna |
| BR112022006534A2 (pt) | 2019-10-24 | 2022-07-05 | Novago Therapeutics Ag | Anticorpos anti-nogo-a |
| JP2023508881A (ja) | 2019-12-20 | 2023-03-06 | トランスレイト バイオ, インコーポレイテッド | Mrna担持脂質ナノ粒子を調製する改善されたプロセス |
| CN115427021A (zh) | 2020-02-25 | 2022-12-02 | 翻译生物公司 | 制备负载mrna的脂质纳米颗粒的改进方法 |
| WO2021226468A1 (en) | 2020-05-07 | 2021-11-11 | Translate Bio, Inc. | Improved compositions for cftr mrna therapy |
| ES3066134T3 (en) | 2020-05-14 | 2026-05-11 | Translate Bio Inc | Peg lipidoid compounds |
| WO2021245184A1 (en) | 2020-06-02 | 2021-12-09 | Neurimmune Ag | HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) |
| WO2025056938A1 (en) * | 2023-09-11 | 2025-03-20 | BioNTech SE | Rna compositions for delivery of incretin agents |
| US12678406B2 (en) | 2020-10-12 | 2026-07-14 | Translate Bio Inc. | Process of preparing ice-based lipid nanoparticles |
| CN116438298A (zh) | 2020-10-15 | 2023-07-14 | 翻译生物公司 | 信使rna的大规模合成 |
| US12576030B2 (en) | 2020-11-09 | 2026-03-17 | Translate Bio, Inc. | Compositions for delivery of codon-optimized mRNA |
| WO2023009422A1 (en) * | 2021-07-26 | 2023-02-02 | Modernatx, Inc. | Processes for preparing lipid nanoparticle compositions for the delivery of payload molecules to airway epithelium |
| CN121844046A (zh) * | 2023-09-11 | 2026-04-10 | C·米库尔卡 | 用于递送肠促胰岛素剂的rna组合物 |
| WO2026006617A1 (en) * | 2024-06-27 | 2026-01-02 | Genentech, Inc. | Lyophilized and frozen mrna-lnp formulations |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| JPS607932A (ja) * | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソーム懸濁液およびその製法 |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| WO1999000113A1 (en) | 1997-06-27 | 1999-01-07 | Vivorx Pharmaceuticals, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| JPH11504631A (ja) | 1995-04-25 | 1999-04-27 | バイカル インコーポレイテッド | Dna/脂質複合体の単一バイアル製剤 |
| US6017700A (en) | 1995-08-04 | 2000-01-25 | Bayer Corporation | Cationic oligonucleotides, and related methods of synthesis and use |
| TW520294B (en) * | 1998-01-08 | 2003-02-11 | Res Dev Foundation | Stabilization of lipid: DNA formulations during nebulization |
| WO2005121369A2 (en) * | 2004-06-02 | 2005-12-22 | Sourcepharm, Inc. | Rna-containing microvesicles and methods therefor |
| CN1981044B (zh) * | 2004-06-07 | 2010-05-05 | 普洛体维生物治疗公司 | 包封干扰rna的脂质 |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| US9393215B2 (en) * | 2005-12-02 | 2016-07-19 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| KR101388320B1 (ko) | 2005-12-15 | 2014-04-22 | 뽈리쁠뤼스-트랑스펙씨옹 | 양이온성 올리고뉴클레오티드, 이를 제조하기 위한 자동화방법 및 이의 용도 |
| CN101686939B (zh) | 2007-04-17 | 2013-03-27 | 巴克斯特国际公司 | 用于肺部投送的核酸微粒 |
| GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| CN104382853A (zh) * | 2008-10-16 | 2015-03-04 | 玛瑞纳生物技术有限公司 | 基因沉默治疗剂的脂质体有效递送方法和组合物 |
| WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| EA022786B1 (ru) | 2009-07-31 | 2016-03-31 | Этрис Гмбх | Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков |
| CA3044884A1 (en) | 2009-12-07 | 2011-06-16 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| EP2338520A1 (de) | 2009-12-21 | 2011-06-29 | Ludwig Maximilians Universität | Konjugat mit Zielfindungsligand und dessen Verwendung |
| AU2012255194B2 (en) * | 2011-05-16 | 2017-01-05 | Danmarks Tekniske Universitet | Charge triggering of self-organized nanoparticles |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| GB201118704D0 (en) | 2011-10-28 | 2011-12-14 | Univ Oxford | Cystic fibrosis treatment |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| EA037448B1 (ru) | 2012-06-08 | 2021-03-30 | Этрис Гмбх | Способ доставки в легкие терапевтической мрнк с pei и фармацевтическая композиция |
| ES2967701T3 (es) * | 2013-03-15 | 2024-05-03 | Translate Bio Inc | Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas |
| KR102285326B1 (ko) | 2013-06-28 | 2021-08-04 | 에트리스 게엠베하 | Rna를 세포에 도입하기 위한 조성물 |
| CN110003066B (zh) * | 2013-11-18 | 2021-09-03 | 阿克丘勒斯治疗公司 | 用于rna递送的可电离的阳离子脂质 |
| JP2017507946A (ja) * | 2014-02-26 | 2017-03-23 | エスリス ゲーエムベーハーethris GmbH | Rnaを胃腸内投与するための組成物 |
| DK3221293T3 (da) | 2014-11-18 | 2023-04-03 | Arcturus Therapeutics Inc | Ioniserbar kationisk lipid til RNA-afgivelse |
| EP3034539A1 (en) | 2014-12-19 | 2016-06-22 | Ethris GmbH | Compositions for introducing nucleic acid into cells |
| EP3247328B1 (en) | 2015-01-21 | 2026-01-07 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| WO2016118724A1 (en) * | 2015-01-21 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| WO2018010815A1 (en) * | 2016-07-15 | 2018-01-18 | Biontech Rna Pharmaceuticals Gmbh | Formulation for administration of rna |
| EP3538067A1 (en) * | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| US20180153822A1 (en) | 2016-11-10 | 2018-06-07 | Translate Bio, Inc. | Process of Preparing mRNA-Loaded Lipid Nanoparticles |
| JP7256824B2 (ja) | 2018-04-25 | 2023-04-12 | エスリス ゲーエムベーハー | 粒子状製剤用の凍結保護剤 |
| CA3109548A1 (en) | 2018-08-14 | 2020-02-20 | Ethris Gmbh | Lipid-based formulations containing salts for the delivery of rna |
-
2019
- 2019-04-25 JP JP2020559465A patent/JP7256824B2/ja active Active
- 2019-04-25 MX MX2020011167A patent/MX2020011167A/es unknown
- 2019-04-25 EP EP23187109.6A patent/EP4311541A3/en not_active Withdrawn
- 2019-04-25 CN CN201980034447.1A patent/CN112153985B/zh active Active
- 2019-04-25 EP EP19718759.4A patent/EP3784284B1/en active Active
- 2019-04-25 JP JP2020558887A patent/JP2021522228A/ja active Pending
- 2019-04-25 BR BR112020021037-4A patent/BR112020021037A2/pt unknown
- 2019-04-25 US US17/050,441 patent/US20210137840A1/en not_active Abandoned
- 2019-04-25 EP EP19718760.2A patent/EP3784285B1/en active Active
- 2019-04-25 AU AU2019258678A patent/AU2019258678B2/en not_active Ceased
- 2019-04-25 WO PCT/EP2019/060644 patent/WO2019207060A1/en not_active Ceased
- 2019-04-25 AU AU2019258679A patent/AU2019258679B2/en active Active
- 2019-04-25 KR KR1020207030471A patent/KR20210021943A/ko active Pending
- 2019-04-25 WO PCT/EP2019/060646 patent/WO2019207061A1/en not_active Ceased
- 2019-04-25 ES ES19718760T patent/ES2960939T3/es active Active
- 2019-04-25 BR BR112020021054-4A patent/BR112020021054A2/pt not_active IP Right Cessation
- 2019-04-25 CA CA3098259A patent/CA3098259C/en active Active
- 2019-04-25 ES ES19718759T patent/ES2960936T3/es active Active
- 2019-04-25 PL PL19718760.2T patent/PL3784285T3/pl unknown
- 2019-04-25 US US17/050,440 patent/US12465568B2/en active Active
- 2019-04-25 MX MX2020011166A patent/MX2020011166A/es unknown
- 2019-04-25 CN CN201980034487.6A patent/CN112153986B/zh not_active Expired - Fee Related
- 2019-04-25 KR KR1020207030470A patent/KR20210022535A/ko not_active Ceased
-
2020
- 2020-09-29 ZA ZA2020/06025A patent/ZA202006025B/en unknown
- 2020-09-29 ZA ZA2020/06026A patent/ZA202006026B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2314408T3 (es) | Formulaciones de hfc en solucion que contienen un anticolinergico. | |
| Myrdal et al. | Advances in metered dose inhaler technology: formulation development | |
| JP3056784B2 (ja) | エアゾール医薬製剤 | |
| JP3026841B2 (ja) | 医 薬 | |
| JP3210012B2 (ja) | 医薬品 | |
| JP3280974B2 (ja) | 医 薬 | |
| JP2021522228A5 (cg-RX-API-DMAC7.html) | ||
| JP3026840B2 (ja) | 医 薬 | |
| JP2915574B2 (ja) | 医療用エアロゾル製剤 | |
| TW528606B (en) | Pharmaceutical formulations for aerosols with two or more active substances | |
| JP2016512494A5 (cg-RX-API-DMAC7.html) | ||
| JPH10510521A (ja) | エアゾール処方物用噴射剤混合物 | |
| JPH06501710A (ja) | ベクロメタゾン17,21ジプロピオネートを含んで成るエアロゾル製剤 | |
| JP2003521459A (ja) | 医薬用エーロゾル製剤 | |
| JPH07503476A (ja) | 医薬 | |
| JP2002541183A (ja) | 医薬用エアゾール製剤 | |
| JP2024507394A5 (cg-RX-API-DMAC7.html) | ||
| JP2016534142A5 (cg-RX-API-DMAC7.html) | ||
| JP2019524648A (ja) | ニコチン粒子および組成物 | |
| JP2014224147A5 (cg-RX-API-DMAC7.html) | ||
| JP2001525354A (ja) | 薬用エアロゾル組成物 | |
| CN102905694B (zh) | 吸入溶液 | |
| CN102238939B (zh) | 药物气溶胶组合物 | |
| BR102012026195B1 (pt) | método de preparação de uma formulação de nicotina adequada para inalação e método para a realização de uma terapia de substituição ou retirada de tabaco | |
| TWI924704B (zh) | 茚達特羅(indacaterol)之液體調配物 |